STOCK TITAN

Rigel (NASDAQ: RIGL) EVP granted 7,394 fully vested performance options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

RIGEL PHARMACEUTICALS INC executive Raymond J. Furey received a fully vested employee stock option tied to a performance goal. The award covers 7,394 shares of common stock at an exercise price of $22.49 per share. The performance metric was confirmed as met on June 17, 2026, triggering vesting, and the option expires on January 29, 2035. This is a compensation-related grant, not an open-market share purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Furey Raymond J.
Role EVP, GC, CCO & Corp Sec
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) 7,394 $0.00 --
Holdings After Transaction: Employee Stock Option (right to buy) — 7,394 shares (Direct, null)
Footnotes (1)
  1. The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.
Option shares granted 7,394 shares Employee stock option covering common stock
Exercise price $22.49 per share Closing price on Nasdaq on January 29, 2025
Shares following transaction 7,394 option shares Total option shares held after this grant
Vesting date June 17, 2026 Date performance metric determined met; option fully vested
Option expiration January 29, 2035 Expiration date of the employee stock option
performance-based condition financial
"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares"
exercise price financial
"The exercise price of this option is $22.49, which is the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Section 16 regulatory
"this grant was not reportable under Section 16 until the performance metric was satisfied"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
employee stock option financial
"security_title: Employee Stock Option (right to buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
performance metric financial
"On June 17, 2026, it was determined that the performance metric had been met."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Furey Raymond J.

(Last)(First)(Middle)
RIGEL PHARMACEUTICALS, INC.
611 GATEWAY BLVD, SUITE 900

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, GC, CCO & Corp Sec
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$22.49(1)06/17/2026A7,394(1) (2)01/29/2035Common Stock7,394(1)$07,394D
Explanation of Responses:
1. The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
2. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.
/s/ Raymond Furey06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did RIGEL (RIGL) report for Raymond J. Furey?

RIGEL reported a grant of an employee stock option to Raymond J. Furey covering 7,394 shares of common stock. The option became fully vested when a performance metric was determined to be met on June 17, 2026, and reflects compensation rather than an open-market trade.

What is the exercise price of Raymond J. Furey’s new RIGEL stock option?

The option has an exercise price of $22.49 per share, equal to the closing price on Nasdaq on January 29, 2025, the grant date. This price is what must be paid per share to convert the option into common stock if exercised.

How many RIGEL shares are covered by Raymond J. Furey’s option in this Form 4?

The reported employee stock option covers 7,394 shares of RIGEL’s common stock. After the vesting tied to the performance condition, Mr. Furey holds 7,394 option shares following the transaction, all reported as directly owned for Section 16 purposes.

When did the performance condition for Raymond J. Furey’s RIGEL option vesting get satisfied?

The company determined on June 17, 2026, that the performance metric for the option grant had been met. As a result, the option became fully vested on that same date, converting from a performance-contingent award into a vested, exercisable stock option.

When does Raymond J. Furey’s RIGEL stock option reported here expire?

The employee stock option reported for Raymond J. Furey expires on January 29, 2035. Until that expiration date, and subject to plan terms, he can choose whether and when to exercise the option to buy RIGEL common shares at the fixed $22.49 price.

Was this RIGEL Form 4 transaction an open-market purchase or sale of shares?

No, this Form 4 shows a grant of an employee stock option that vested when a performance condition was met. It does not involve an open-market purchase or sale of RIGEL common stock and reflects equity-based executive compensation instead.